Tanya Diaz, MD
Family Medicine · Leesburg, FLNPI 1467445080
Payments from drug & device makers
Across 116 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$374
- Exact Sciences$249
- Novo Nordisk$231
- Boston Scientific$183
- Tosoh Bioscience, Inc.$169
- Lilly USA, LLC$165
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,23393%
- Gifts$1697%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $374 |
| Exact Sciences | 11 | $249 |
| Novo Nordisk | 12 | $231 |
| Boston Scientific | 8 | $183 |
| Tosoh Bioscience, Inc. | 1 | $169 |
| Lilly USA, LLC | 8 | $165 |
| Pfizer | 7 | $158 |
| GSK | 8 | $153 |
| Amgen | 7 | $120 |
| Kowa Pharmaceuticals America, Inc. | 6 | $95 |
| Amarin Pharma, Inc. | 4 | $61 |
| AbbVie | 3 | $52 |
| Abbott | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $33 |
| Vifor Pharma, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Dynavax Technologies Corporation | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Biotronik NRO, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Merck | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TSH, ST AIA-PACK$169
- TSH3G, AIA-PACK Calibrator Set$169
- FOL, AIA-PACK$169
- FOL, AIA-PACK, Sample Diluting Solution$169
- T4, AIA-PACK Calibrator Set$169
How this compares
$2,402 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $245,998 |
| MounjaroTirzepatide | 129 | $163,021 |
| EliquisApixaban | 46 | $61,209 |
| JardianceEmpagliflozin | 38 | $52,489 |
| LinzessLinaclotide | 29 | $39,922 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $35,434 |
| FarxigaDapagliflozin Propanediol | 22 | $29,240 |
| XareltoRivaroxaban | 17 | $28,499 |
| TrulicityDulaglutide | 13 | $23,730 |
| MyrbetriqMirabegron | 18 | $21,301 |
| JanuviaSitagliptin Phosphate | 11 | $16,866 |
| WegovySemaglutide | 13 | $16,842 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $11,188 |
| PremarinEstrogens, Conjugated | 12 | $7,280 |
| Levothyroxine Sodium | 737 | $6,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $231 | $262,840217 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $186,750142 claims |
| PfizerEliquis, Premarin | $158 | $68,48958 claims |
| Boehringer IngelheimJardiance | $23 | $52,48938 claims |
| AbbVieLinzess, Synthroid | $52 | $45,572110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $153 | $41,18242 claims |
| AstraZenecaFarxiga | $374 | $29,24022 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $21,30118 claims |
| MerckJanuvia | $20 | $16,86611 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $3,91818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Leesburg
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.